• SHARE

Moderna Inc.’s COVID-19 vaccine generated more than double the antibodies of a similar shot made by Pfizer Inc. and BioNTech SE in research that compared immune responses evoked by the two inoculations.

The study is one of the first to compare levels of antibodies produced by the two vaccines, which are thought to be one of the important components of the immune response. It didn’t examine whether the antibody differences led to a difference in efficacy over time between the two shots, which both were more than 90% effective in final-stage clinical trials

In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.

SUBSCRIBE NOW

PHOTO GALLERY (CLICK TO ENLARGE)